Kathleen M. Cain

Kathleen M. Cain

Auto-generated profile, based on publicly available information

Kathleen M. Cain

Manchester Institute of Biotechnology, University of Manchester, Princess St, Manchester, UK, M1 7DN

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
CECharles Eldrid
Charles Eldrid
EHEllie Hawke
Ellie Hawke
KCKathleen M. Cain
Kathleen M. Cain
KMKate Meeson
Kate Meeson
JWJoanne Watson
Joanne Watson
PBPerdita Barran
Perdita Barran
Chinese hamster ovary (CHO) cells are the industrial workhorse for manufacturing biopharmaceuticals, including monoclonal antibodies. CHO cell line development requires a more data-driven approach for the accelerated identification of hyper-productive cell lines. Traditional methods, which rely on time-consuming hierarchical screening, often fail to elucidate the underlying cellular mechanisms driving optimal bioreactor performance. Big data analytics, coupled with advancements in 'omics' technologies, are revolutionizing the study of industrial cell lines. Translating this knowledge into practical methods widely utilized in industrial biomanufacturing remains a significant challenge. This study leverages discovery proteomics to characterize dynamic changes within the CHO cell proteome during a 14-day fed-batch bioreactor cultivation. Utilizing a global untargeted proteomics workflow on both a ZenoTOF 7600 and a Cyclic IMS QToF, we identify 3358 proteins and present a comprehensive data set that describes the molecular changes that occur within a well characterized host chassis. By mapping relative abundances to key cellular processes, eight protein targets were selected as potential biomarkers. The abundance of these proteins through the production run are quantified using a 15-minute targeted triple quadrupole (MRM) assay which provides a molecular level QC for cell viability. This discovery to target workflow has the potential to assist engineering of new chassis and provide simple read outs of successful bioreactor batches.

19 November 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
CECharles Eldrid
Charles Eldrid
EHEllie Hawke
Ellie Hawke
KCKathleen M. Cain
Kathleen M. Cain
KMKate Meeson
Kate Meeson
JWJoanne Watson
Joanne Watson
PBPerdita Barran
Perdita Barran
Chinese hamster ovary (CHO) cells are the industrial workhorse for manufacturing biopharmaceuticals, including monoclonal antibodies. CHO cell line development requires a more data-driven approach for the accelerated identification of hyper-productive cell lines. Traditional methods, which rely on time-consuming hierarchical screening, often fail to elucidate the underlying cellular mechanisms driving optimal bioreactor performance. Big data analytics, coupled with advancements in ‘omics’ technologies, are revolutionizing the study of industrial cell lines. However, translating this knowledge into practical methods widely utilized in industrial biomanufacturing remains a significant challenge. This study leverages discovery proteomics to characterize dynamic changes within the CHO cell proteome during a 14 day fed-batch bioreactor cultivation. Utilizing a global untargeted proteomics workflow, we identify 3358 proteins, using a ZenoTOF 7600 and a Cyclic IMS QToF. By mapping relative abundances to key cellular processes, eight protein targets were selected as potential biomarkers. To bridge the gap between discovery and industrial applications, we translated these findings into a rapid 15 minute targeted triple quadrupole (MRM) assay. This approach demonstrates the potential of repurposing discovery proteomics for targeted biomarker identification in biotherapeutic production. By monitoring these biomarkers we can potentially streamline the screening of biomanufacturing cell lines and culture conditions, ultimately accelerating biotherapeutic development.

2 September 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
NAN Leigh Anderson
N Leigh Anderson
ABAlistair Bailey
Alistair Bailey
PBPerdita Barran
Perdita Barran
PBPhilip Brownbridge
Philip Brownbridge
KCKathleen Cain
Kathleen Cain
RYRichard Yip
Richard Yip
During the COVID-19 pandemic, development of diagnostic tests was vital to chart the course and to reduce the impact of the infection. Continued testing and surveillance of vaccine escape will continue for years to come which presents an opportunity to integrate such testing into clinical biochemistry laboratories that form part of integrated healthcare testing. Here we describe a protocol for a targeted mass spectrometry based proteomic assay (COVIDCAP) developed to detect SARS-CoV-2 peptides from oro-nasopharyngeal swabs (ONP) and saliva. This uses novel SISCAPA antibodies bound to magnetic beads and subsequent analysis of captured and purified SARS-CoV-2 nucleocapsid (NCAP) peptides. The method involves immediate deactivation of the sample using an ethanolic solution. This simultaneously inactivates the virus and denatures viral proteins at sampling in contrast to the approach for RT-PCR testing, with benefits for the assay as well as for downstream processing. A plate-based preparation of the samples involving acetone precipitation followed by a short tryptic digestion and subsequent immunocapture allows LC-MS detection and quantification of peptides from the NCAP protein, in a 3-minute inject-to-inject assay with an LOD of 20 attomoles from starting sample. For 576 ONP swab samples taken as exemplars here, the sensitivity and specificity of this analysis is shown to be 97.0% and 96.6% respectively.